Barclays analyst Luke Sergott downgraded Fortrea (FTRE) to Underweight from Equal Weight with a price target of $6, down from $12. The firm moved to the sidelines on the contract research organizations, citing lower confidence around pharma restructurings based on the pharma-specific tariff overhang. The firm considers the potential reaction of further cost-cutting and budget rightsizing from the “looming pharma-specific tariffs yet to be announced.” Pharma can not pass on the tariffs via increased drug pricing, as the Inflation Reduction Act caps Part D price increases at inflation, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea price target lowered to $10 from $12 at Mizuho
- Fortrea Holdings Appoints Erin L. Russell as Director
- Fortrea price target lowered to $11 from $20 at TD Cowen
- Cautious Hold Rating for Fortrea Holdings Inc.: Navigating Transition and Growth Challenges
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue